Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S. Wang, Amir T. Fathi, Ghayas C. Issa et al.|The Lancet Oncology|2024Cited by 106
<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Juan Manuel Alonso‐Domínguez, Pinkal Desai et al.|Clinical and Translational Science|2022Cited by 35
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Bruno Paiva et al.|Blood Advances|2021Cited by 25
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusionsGuillermo Ortí, David Valcárcel, Jaime Sanz et al.|Experimental Hematology|2018Cited by 21
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2023Cited by 15